WillItSurvive
Pharma and healthcare groups · Denmark

Novo Nordisk

novonordisk.com ↗

Danish maker of Ozempic and Wegovy, leading GLP-1 diabetes and obesity drugs.

Protection under test
Assessed 20 July 2026 · Evidence as of 20 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 20 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: FDA decision on CagriSema, Novo's next-generation obesity drug
The call

Novo still leads obesity drugs by scale and patents, but Eli Lilly's tirzepatide is eating into its US share as growth slows sharply.

Novo Nordisk is a Danish company that makes semaglutide, a popular injectable drug for weight loss and diabetes. Eli Lilly's competing drug, tirzepatide, is winning customers away from Novo right now, especially through insurance deals, and Novo's sales growth has slowed dramatically from 31% down to just 6.4% per year. The question is whether Novo's new pill version of Wegovy and a combination drug called CagriSema can stop Eli Lilly's momentum before Novo becomes locked into second place permanently.

Why
01
AI pressure: None apparent. AI drug-discovery tools speed internal R&D, but no AI system yet threatens Novo's actual drug sales. Could AI do the core job? Unlikely.
02
Bigger players: Eli Lilly. Lilly's tirzepatide (Zepbound, Mounjaro) won CVS formulary preference in 2026, pulling US patients from Novo. Could a giant copy it? No, they are blocked.
03
What protects it. Semaglutide patents run into the early 2030s, plus complex peptide manufacturing and reach across 170 countries.
What would change this call
CagriSema FDA approval decision (expected Q4 2026). Shows whether Novo has a new drug to counter Lilly's pipeline lead.
CVS or other major PBM formulary renewal decisions through 2026. Shows whether Novo regains or keeps losing pharmacy-benefit placement to Lilly.
FY2026/27 revenue growth rate reported at Q2 2026 earnings (Aug 5, 2026) and beyond. Shows whether Novo's growth slide (31%→25%→6.4%) stabilizes or worsens.
Key numbers
  • FY2025 revenue growth fell to 6.4%, down from 25% in 2024 (2025)
  • Oral Wegovy pill hit 3 million prescriptions in 5 months (June 2026)
  • Market cap dropped to $220-230B from its 2024 peak (July 2026)
Named risks
  • Eli Lilly formulary wins and share gains eroding Novo's US market position. Severity: high
  • January 2027 list-price cuts of up to 50% for Wegovy pressuring margins. Severity: high
  • Ozempic products-liability MDL with 3,848 pending federal lawsuits as of June 2026. Severity: medium
  • CagriSema FDA decision delay or disappointing data in Q4 2026. Severity: medium
  • Ongoing headcount reduction and hiring freeze signaling operational strain. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Eli Lillylosing toLilly won CVS Health formulary preference over Novo, reported 2026-07-17
Eli LillycontestingNovo's oral Wegovy pill hit 3 million prescriptions by June 2026 to counter Lilly's tirzepatide gains
Hims and HerscontestingNovo filed patent-infringement lawsuit against Hims and Hers over compounded semaglutide, Feb 9, 2026
Questions people ask
Is Novo Nordisk profitable in 2026?
Yes, Novo Nordisk remains profitable with FY2025 revenue of DKK 309.06 billion, up 6.43% year over year, though growth has decelerated sharply from 25% in 2024 and 31% in 2023, per stockanalysis.com data published 2026-07-13.
Is Eli Lilly beating Novo Nordisk in the obesity drug market?
Eli Lilly has overtaken Novo Nordisk for US CVS Health formulary preference as of 2026, per a MarketBeat/Erste Group note dated 2026-07-17, and Zacks downgraded Novo to Strong Sell on 2026-07-15 citing competitive pressure from Lilly's tirzepatide drugs.
Could AI replace Novo Nordisk's drug development work?
No, AI is a tool Novo deploys via an OpenAI partnership announced 2026-04-14 and Nvidia's Gefion supercomputer to speed R&D and cut clinical document generation time by about 90%, but its semaglutide patents and peptide manufacturing know-how remain the core moat, not replaceable by AI.
Who owns Novo Nordisk?
Novo Nordisk is publicly traded but majority-controlled by Novo Holdings A/S, owned by the Novo Nordisk Foundation, which held about 28% of shares but 77% of voting rights via A-shares as of 2026, per Wikipedia (accessed 2026-07-20).
What is Novo Nordisk's biggest competitor?
Eli Lilly is Novo Nordisk's primary competitor, with tirzepatide brands Zepbound and Mounjaro winning US formulary share, including a CVS Health preference win over Novo reported 2026-07-17; Lilly also has oral orforglipron in development.
Will Novo Nordisk's CagriSema drug get FDA approval?
Unresolved: Novo filed an NDA for CagriSema (cagrilintide plus semaglutide) with the FDA on December 18, 2025 for weight management, with an FDA decision expected in Q4 2026, according to drugs.com (2026-02-22).
Timeline
  • 2026-07-17Erste Group notes Eli Lilly won CVS Health formulary preference over Novo Nordisk
  • 2026-07-15Zacks Research downgrades Novo Nordisk to Strong Sell
  • 2026-04-14Novo Nordisk announces AI partnership with OpenAI across drug discovery to commercial ops
  • 2026-02-24Novo announces up to 50% Wegovy list-price cut effective January 2027
  • 2026-02-09Novo Nordisk files patent-infringement lawsuit against Hims and Hers
  • 2025-12-18CagriSema NDA filed with FDA for weight management
  • 2025-11Novo agrees to Trump administration Most Favored Nation pricing deal via TrumpRx.gov
  • 2025-09-10Novo announces roughly 9,000 layoffs and DKK 8 billion cost-savings target
  • 2025-08-07Maziar Mike Doustdar becomes first non-Danish CEO of Novo Nordisk
  • 2025-05-16CEO Lars Fruergaard Jorgensen announces departure
Revision history
20 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumBaxter InternationalBristol-Myers Squibb
More in Pharma and healthcare groups →
Sources